Impact Investors Inc Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Impact Investors Inc bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 52,122 shares of the company’s stock, valued at approximately $1,260,000. Hims & Hers Health accounts for about 1.0% of Impact Investors Inc’s investment portfolio, making the stock its 27th largest holding.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. boosted its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares during the period. Venturi Wealth Management LLC acquired a new stake in Hims & Hers Health in the 4th quarter worth $48,000. GAMMA Investing LLC increased its holdings in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the period. Finally, Principal Securities Inc. raised its position in shares of Hims & Hers Health by 48.2% during the fourth quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after buying an additional 1,002 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $39.95 on Wednesday. Hims & Hers Health, Inc. has a fifty-two week low of $9.67 and a fifty-two week high of $72.98. The business’s 50-day simple moving average is $35.62 and its 200-day simple moving average is $26.25. The stock has a market capitalization of $8.73 billion, a PE ratio of 90.79 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity

In other news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total value of $7,462,863.00. Following the completion of the sale, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares in the company, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,097,578 shares of company stock worth $38,080,320 in the last quarter. 17.71% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HIMS shares. Bank of America lifted their price objective on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a report on Thursday, February 20th. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $33.40.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.